BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17126249)

  • 1. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
    Leo C; Faber S; Hentschel B; Höckel M; Horn LC
    Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
    Oliveira VM; Piato S; Silva MA
    Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
    Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
    Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
    Ranger GS; Jewell A; Thomas V; Mokbel K
    J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical COX-2 overexpression correlates with HER-2/neu overexpression in invasive breast carcinomas: a pilot study.
    Çiriş IM; Bozkurt KK; Başpinar S; Kapucuoğlu FN
    Pathol Res Pract; 2011 Mar; 207(3):182-7. PubMed ID: 21371829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium.
    Shim V; Gauthier ML; Sudilovsky D; Mantei K; Chew KL; Moore DH; Cha I; Tlsty TD; Esserman LJ
    Cancer Res; 2003 May; 63(10):2347-50. PubMed ID: 12750248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cyclooxygenase-2 in malignant and benign breast tumors.
    Watanabe O; Shimizu T; Imamura H; Kinoshita J; Utada Y; Okabe T; Kimura K; Hirano A; Yoshimatsu K; Aiba M; Ogawa K
    Anticancer Res; 2003; 23(4):3215-21. PubMed ID: 12926055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
    Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
    Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
    Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2 expression in lobular in situ neoplasia of the breast: correlation with histopathological grading system according to the Tavassoli classification.
    Perrone G; Zagami M; Santini D; Vincenzi B; Gullotta G; Morini S; Battista C; Guerriero G; Altomare V; Tonini G; Rabitti C
    Histopathology; 2007 Jul; 51(1):33-9. PubMed ID: 17542993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quantitative detection of telomerase activity and its association with clinicopathological characteristics in breast cancer].
    He GP; Shui QL; Huang Y; Zhang SZ; Yu H
    Ai Zheng; 2004 Sep; 23(9):1041-6. PubMed ID: 15363198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast.
    Wykoff CC; Beasley N; Watson PH; Campo L; Chia SK; English R; Pastorek J; Sly WS; Ratcliffe P; Harris AL
    Am J Pathol; 2001 Mar; 158(3):1011-9. PubMed ID: 11238049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 induction by heparanase in the progression of breast cancer.
    Imada T; Matsuoka J; Nobuhisa T; Okawa T; Murata T; Tabuchi Y; Shirakawa Y; Ohara N; Gunduz M; Nagatsuka H; Umeoka T; Yamamoto Y; Nakajima M; Tanaka N; Naomoto Y
    Int J Mol Med; 2006 Feb; 17(2):221-8. PubMed ID: 16391819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma.
    Takeshita E; Osanai T; Higuchi T; Soumaoro LT; Sugihara K
    J Med Dent Sci; 2005 Dec; 52(4):189-93. PubMed ID: 16669452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.
    de la Torre J; Sabadell MD; Rojo F; Lirola JL; Salicru S; Reventos J; Ramón y Cajal S; Xercavins J
    Eur J Obstet Gynecol Reprod Biol; 2010 Jul; 151(1):72-6. PubMed ID: 20227160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.
    Barnes N; Haywood P; Flint P; Knox WF; Bundred NJ
    Br J Cancer; 2006 Jan; 94(2):253-8. PubMed ID: 16421596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
    Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.